The effect of elagolix on the endometrium: safety results from two randomized, placebo-controlled studies in women with endometriosis-associated pain

Abstract

To evaluate the effect of elagolix, an oral, non-peptide gonadotropin-releasing hormone antagonist, on endometrial morphology and thickness after treatment for 6 months in women with moderate/severe endometriosis-associated pain (EAP).